Rheumatologists’ knowledge and adherence to recommendations (n= 31).
| Recommendations | Knowledge | Adherence | ||||
|---|---|---|---|---|---|---|
| n (m) | % | 95% CI | m | Mean | SD | |
| Domain A: Indications for TNF inhibitors | ||||||
| Indications | ||||||
| Modified New York/ASAS classification criteria | 31 | 100 | 100.0–100.0 | 9.1 | 0.28 | |
| Active disease ≥ 4 wks | 30 | 96.8 | 90.6–100.0 | 9.6 | 0.21 | |
| Domain B: Pretherapeutic monitoring | ||||||
| Infection | ||||||
| Ongoing infection | 31 | 100 | 100.0–100.0 | 1 | 9.8 | 0.18 |
| Assessment of high risk of infection | 30 | 96.8 | 90.6–100.0 | 1 | 9.5 | 0.24 |
| HIV serology | 30 | 96.8 | 90.6–100.0 | 9.8 | 0.16 | |
| Hepatitis B serology | 31 | 100 | 100.0–100.0 | 10.0 | 0.03 | |
| Hepatitis C serology | 31 | 100 | 100.0–100.0 | 10.0 | 0.03 | |
| Pneumococcal vaccine | 30 | 96.8 | 90.6–100.0 | 9.6 | 0.30 | |
| Tetanus vaccine | 31 | 100 | 100.0–100.0 | 9.8 | 0.09 | |
| Influenza vaccine | 30 (1) | 100 | 100.0–100.0 | 2 | 9.7 | 0.19 |
| Dental status | 31 | 100 | 100.0–100.0 | 9.8 | 0.10 | |
| Cancer | ||||||
| Cancer screening | 29 (1) | 96.7 | 90.2–100.0 | 1 | 9.5 | 0.23 |
| Research of hemopathy/adenopathy | 29 (1) | 96.7 | 90.2–100.0 | 1 | 9.9 | 0.09 |
| Research of cancer or precancer | 30 (1) | 100 | 100.0–100.0 | 3 | 9.6 | 0.23 |
| Pregnancy | 31 | 100 | 100.0–100.0 | 9.4 | 0.24 | |
| Other | ||||||
| Autoimmune disease/MS | 30 | 96.8 | 90.6–100.0 | 1 | 9.2 | 0.29 |
| Domain C: Management under TNF inhibitors | ||||||
| Management | ||||||
| First visit after 12 to 16 wks of anti-TNF | 29 (2) | 100 | 100.0–100.0 | 2 | 9.9 | 0.08 |
| Safety assessment | 29 (1) | 96.7 | 90.2–100.0 | 2 | 9.8 | 0.15 |
| Disease activity assessment | 28 (1) | 93.3 | 84.4–100.0 | 2 | 9.0 | 0.30 |
m: missing data; ASAS: Assessment of Spondyloarthritis international Society; HIV: human immunodeficiency virus; MS: multiple sclerosis; TNF: tumor necrosis factor.